Related Experiment Video
Updated: Aug 4, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
Diarrhea-associated hemolytic uremic syndrome
W L Robson1, A K Leung, C L Trevenen
1Children's Hospital, Greenville, SC.
Insights
Diarrhea-associated hemolytic uremic syndrome (D+ HUS) is a leading cause of pediatric acute kidney injury. This study reviews 114 D+ HUS cases in Calgary from 1980-1992, detailing epidemiologic, clinical, and pathologic features.
Area of Science:
- Pediatric Nephrology
- Infectious Diseases
- Renal Medicine
Background:
- Diarrhea-associated hemolytic uremic syndrome (D+ HUS) is a significant cause of acute renal failure in children.
- Understanding the epidemiology, clinical presentation, and pathology of D+ HUS is crucial for patient management.
Purpose of the Study:
- To describe the epidemiologic, clinical, and pathologic characteristics of D+ HUS.
- To report the experience with D+ HUS in a cohort of 114 pediatric patients.
Main Methods:
- Retrospective review of 114 pediatric patients diagnosed with D+ HUS.
- Data collection included epidemiologic, clinical, and pathological information.
Main Results:
- The study analyzed data from 114 patients over a 13-year period (1980-1992).
- Epidemiologic, clinical, and pathological findings of D+ HUS were discussed.
Conclusions:
- The findings provide insights into the presentation and characteristics of D+ HUS in a pediatric population.
- This review contributes to the understanding of D+ HUS management and outcomes.
Abstract:
Diarrhea-associated hemolytic uremic syndrome (D+ HUS) is the most common cause of acute renal failure in children. The authors report their experience with D+ HUS with 114 patients assessed in Calgary from 1980 to 1992. Epidemiologic, clinical, and pathologic aspects are discussed.
Related Concept Videos
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Bacterial Gastroenteritis
Cholera
Giardiasis
Amebiasis

